Related Experiment Video
Updated: May 6, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Future Directions of Chronic Total Occlusion Management: Identifying the Right Patient for Intervention With a Focus
Daniel A Gold1, Nodari Maisuradze1, Billy Joe Mullinax1
1Emory Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Insights
Managing coronary artery chronic total occlusion (CTO) is challenging. High-risk CTO patients with significant ischemia and elevated biomarkers may benefit from revascularization, warranting further study.
Area of Science:
- Interventional Cardiology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Coronary artery chronic total occlusion (CTO) management remains complex, with revascularization lacking proven mortality benefits.
- Subgroups of CTO patients exhibit high ischemia and elevated biomarkers (hsTn-I, NT-proBNP), indicating heightened cardiovascular event risk.
Purpose of the Study:
- To evaluate the potential mortality benefit of CTO revascularization in specific high-risk patient subgroups.
- To identify whether patients with high ischemic burden and elevated biomarkers benefit from CTO percutaneous coronary intervention (PCI).
Main Methods:
- Analysis of patient subgroups with CTO, focusing on myocardial perfusion imaging and biomarker levels.
- Review of existing clinical trial data and recommendations for future randomized controlled trials.
Main Results:
- Prior trials may not have adequately represented high-risk CTO patient subgroups.
- Patients with low ischemia and biomarker levels appear to be at lower risk and may not benefit from CTO revascularization.
Conclusions:
- Future randomized controlled trials should investigate CTO PCI efficacy in high-risk patients with elevated biomarkers and significant ischemia.
- Determining mortality benefits in specific CTO patient populations is crucial for guiding treatment strategies.
Abstract:
The management of a chronic total occlusion (CTO) of a coronary artery has been a conundrum in interventional cardiology, as revascularization has not been proven to provide a mortality benefit. However, there are subgroups of patients with a CTO that have high levels of ischemia on myocardial perfusion imaging and high circulating levels of high sensitivity troponin-I (hsTn-I) and N terminal pro-brain natriuretic peptide (NT pro-BNP) that are at a particularly high-risk for adverse cardiovascular events. These high-risk subgroups of patients with a CTO may have not been well represented in prior clinical trials, and may gain a mortality benefit from revascularization of the CTO. Conversely, patients with low levels of ischemia and these biomarkers are at lower risk and may not gain a mortality benefit from revascularization of their CTO. It is important for future randomized controlled trials to investigate the efficacy of CTO PCI in patients with elevated biomarkers and high ischemic burden on myocardial perfusion imaging to determine if patients at high-risk gain a mortality benefit from revascularization.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:26Atherosclerosis III: Management
01:23Atherosclerosis IV: Nursing Management
01:27Peripheral Artery Disease III: Interprofessional Care